The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Earlier this month, Vice President and presidential nominee Kamala Harris released a report with details about her health and ...

In the following section, the various methods used to evaluate antihistamines illustrate the developmental process for evaluating the efficacy of the H 1-receptor antagonist desloratadine.

For mild hives, your doctor may recommend an over-the-counter, second-generation H1 antihistamine such as fexofenadine (Allegra), loratadine (Claritin), cetirizine (Zyrtec), or desloratadine ...

This observation led Swedish investigators to propose, in 1948, that there are two types of receptors sensitive to histamine, and close to two decades later British researchers gave the name H1 to ...

and H1 histamine receptors. This effect may be one of the main reasons trazodone works as a sleep aid. Keep reading to learn more about what to consider before taking trazodone for sleep.

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Abstract and Introduction Predicting and Establishing the Clinical Efficacy of a Histamine H Application ... inflammatory mechanisms of action of H 1-receptor antagonists and to predict their ...